"The results are really beyond our wildest dreams. [Paxlovid] can have a big impact on helping all our lives go back to normal again and seeing the end of the pandemic."

Annaliesa Anderson, a Pfizer executive who led the development of the company’s Paxlovid pill, which has shown effectiveness against COVID-19 in a clinical trial, commenting in the recent New York Times story, “Pfizer Says its Antiviral Pill Is Highly Effective in Treating COVID.” The Pfizer drug appears to be more effective than a similar treatment from Merck, which awaits FDA approval, according to the NY Times report.